19 December 2008: Attached are the minutes from the Extraordinary General Meeting inNorDiag held today, Friday 19 December 2008. 33 658 999 (63 %) ofoutstanding shares were represented in the General Meeting.

The main item on the agenda was the Board`s proposal for a rightsissue of up to 120,234,510 new shares at a subscription price of NOK0.50, together with an issue of warrants to the participants andunderwriters in the rights issue.

On the agenda were also the Board`s proposals to issue warrants toemployees that accept to reduce their salaries, changes of the Boardcomposition, where the nomination committee has proposed Robert V.Ahlgren as new chairman of the Board of Directors, as well as amendments to the incentive program for employees and authorisation of the Board to increase the share capital of the company.

The General Meeting resolved the proposed rights issue with issue ofwarrants. The subscription period is set from 16 January to andincluding 30 January 2009. The shareholders as of 19 December 2008 will receive 2.25 subscription rights per share. The shares will be traded exclusive of subscription rights from and including 22 December 2008.

Each subscribed share will give right to 0.5 A-warrant which has to be exercised before  September 30 2009, and 0.5  B-warrant to be exercised before June 30 2010. Each warrant gives a right to subscribe one NorDiag share at NOK 0.5. The General Meeting also approved the other proposals on issue of warrants to employees, changes of the Board composition, amendments to the incentive program for employees and authorisation of the Board to increase the share capital of the company.

Robert V. Ahlgren was anonymously elected as new chairman in the board of the company. Mr. Ahlgren has extensive international management experience within the medical and diagnostics industry and has held numerous management positions in companies such as Fischer, Apogent Technologies, Murex Diagnostics and Baxter.

Contact:
CEO Mårten Wigstøl              
Phone: +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnosticof infectious diseases and cancer. The company`s core competence is isolation of bacterial and human DNA from difficult clinical samples,and the company has established a solid market share in theScandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application or respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com.

Find the attached protocol here

Read the notice in Norwegian here